FISH application in the diagnosis and prognosis evaluation of myelodysplastic syndrome
|
注册号: Registration number: |
ChiCTR-ONRC-11001709 |
|
最近更新日期: Date of Last Refreshed on: |
2015-07-23 12:39:48 |
|
注册时间: Date of Registration: |
2011-11-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
FISH技术在骨髓增生异常综合征的诊断/鉴别诊断及预后评估中的临床研究 |
|
Public title: |
FISH application in the diagnosis and prognosis evaluation of myelodysplastic syndrome |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
FISH技术在骨髓增生异常综合征的诊断/鉴别诊断及预后评估中的临床研究 |
|
Scientific title: |
FISH application in the diagnosis and prognosis evaluation of myelodysplastic syndrome |
|
研究课题代号(代码): Study subject ID: |
CAMB042010 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赖悦云 |
研究负责人: |
黄晓军 |
|
Applicant: |
Yueyun Lai |
Study leader: |
Xiaojun Huang |
|
申请注册联系人电话: Applicant telephone: |
+86 010 88324578 |
研究负责人电话: Study leader's telephone: |
+86 010 88326006 |
|
申请注册联系人传真 : Applicant Fax: |
+86 010 88324577 |
研究负责人传真: Study leader's fax: |
+86 010 88324577 |
|
申请注册联系人电子邮件: Applicant E-mail: |
laiyueyun1008@yahoo.com.cn |
研究负责人电子邮件: Study leader's E-mail: |
xjhrm@medmail.com.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
西直门南大街11号北京大学人民医院血研所染色体实验室 |
研究负责人通讯地址: |
西直门南大街11号北京大学人民医院血液病研究所 |
|
Applicant address: |
11 Xizhimen South Street, Beijing, China |
Study leader's address: |
11 Xizhimen South Street, Xicheng District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100044 |
研究负责人邮政编码: Study leader's postcode: |
100044 |
|
申请人所在单位: |
北京大学人民医院,北京大学血液病研究所 |
||
|
Applicant's institution: |
Peking University People's Hospital, Peking University Institute of Hematology |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2011]院伦审临医学字第(12)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
北京大学人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of Peking Univeristy People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2011-01-25 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
北京大学人民医院,北京大学血液病研究所 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking University People's Hospital, Peking University Institute of Hematology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
西直门南大街11号北京大学人民医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
11 Xizhimen South Street, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中华医学会分子生物学临床应用研究专项资金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Specific Fund of clinical application of molecular biology from Chinese Medical Association |
||||||||||||||||||||||
|
Target disease: |
myelodysplastic syndrome |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
1. 近期目标(第一阶段,2010年12月至2011年8月): (1) 对确诊的MDS患者进行常规细胞遗传学显带分析(CC)和包括-5/5q-,+8,-7/7q-,20q-,-Y探针组合的FISH检测,建立在MDS诊断过程中的规范化的FISH检测平台。 (2) 比较FISH与常规细胞遗传学方法在检测MDS染色体异常克隆的差异;确立FISH在MDS诊断中的地位。 (3) 经多中心大样本分析,确定中国人群MDS患者的细胞遗传学特性。 2. 中远期目标(第二阶段,2010年12月至2013年3月) 对确诊的MDS患者分别给予支持治疗、化学治疗、去甲基化药物治疗或造血干细胞移植等治疗措施,随访观察疗效及疾病转归。 (1) 根据不同的CC和FISH结果,分析患者向急性白血病转化的几率以及患者的总生存时间差异,评价CC和FISH对于MDS患者的独立预后意义。 (2) 分别按照CC标准和FISH标准判断每例MDS患者的IPSS评分,观察不同评分等级的患者向急性白血病转化的几率以及总生存时间,并比较两种标准对于预后判断的差异,筛选出最佳的染色体预后评判标准。 (3) 每年一次的动态随访MDS染色体及FISH克隆演变,明确克隆演变对MDS疾病进展的预示意义。 (4) 建立中国人群MDS患者的FISH和CC数据库,明确FISH在MDS诊断/鉴别诊断及预后评估中的价值。 (5) 全面推广FISH技术在MDS诊治过程中的应用,为MDS的诊断和个体化治疗提供理论依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. First step aim: (1) Using FISH technique to identify the cytogenetic abnormalities of MDS. (2) Compare the cytogenetic abnormalities detected by FISH and conventional cytogenetic technique(CC). (3) Define the cytogenetic features of Chinese MDS patients based on large cohort of patients. 2. second step aim: (1) Evaluate the prognostic significance of the results of CC and FISH; (2) Follow up the patients once a year including bone marrow and cytogenetic informations to identify the clonal evolution and disease progression; (3) To establish the database of cytogenetic features in Chinese MDS patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
符合MDS维也纳最低诊断标准的初诊MDS患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
The newly diagnosed MDS patients according to Vienna criterion. |
||||||||||||||||||||||
|
排除标准: |
不符合维也纳MDS最低诊断标准的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
The patients do not reach the Vienna criterion of MDS. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2010-12-01 00:00:00至 To 2013-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2010-12-01 00:00:00 至 To 2012-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
non random |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
|
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
|
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |